The devotion, expertise, and degree of professionalism employed by the (Altasciences) team in all stages of development, and the support provided during the Clinical trial, were unprecedented.
Read the Blog
December 10, 2019
If you work in, or around, the early phase drug development landscape, you are likely aware of the requirements for an investigational new drug (IND) package.
Related Press Release
Jan 9, 2020
Altasciences announced the addition of Paul Sidney to their Compliance and Regulatory Affairs team as Senior Director.
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
As part of our full service offering or as standalone solutions